The majority of private funding will create three new Kalvi neuroscience institutes in universities and Johns Hopkins Rockefeller, as well as within the University of California in San Francisco.

“By transcending the traditional boundaries of research in this area, these new neuroscience institutes will be able to make further progress,” said Rockel Hankin, chairman of the Kavli Foundation.

These three institutes will receive twenty million dollars each, said the foundation in a statement.

They will be part of the international network of twenty Kavli institutes dedicated to neuroscience, among others, to astrophysics, nanoscience and theoretical physics.

These new funds will support research in the part of the initiative on the brain, called “Brain” and launched by US President Barack Obama in April 2013, as part of a partnership between the public and private sectors.

The initiative “Brain “(Brain research through innovative neurotechnology Advancing) is implementing side including public sector by national Institutes of Health (NIH), the National Science Foundation (NSF) and the Pentagon’s research agency DARPA (Defense Advanced Research Projects Agency). Private sector side, it is supported by the Kalvi Foundation and other institutions like the Allen Institute.

This brain research project specifically calls for establishing new interdisciplinary scientific collaboration to create innovative technologies to visualize brain function.

The NIH has already selected 58 projects by more than one hundred researchers in the US and abroad, whose task is to develop new technologies to better understand the functioning of neural circuits and capture images of the brain in action.

This research program focuses on three areas: create the next generation of brain imaging techniques, develop high recording methods scale brain activity and develop computer models to understand the functions of specific neural circuits.

According to the NIH, a thorough understanding brain function will open the way to new treatments against devastating brain diseases such as Alzheimer’s, Parkinson, schizophrenia, autism or epilepsy which, according to the World Health Organization (WHO) together affect more than a billion people worldwide.